Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

ClinicalTrials.gov ID: NCT04977986

Public ClinicalTrials.gov record NCT04977986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT

Study identification

NCT ID
NCT04977986
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Enrollment
215 participants

Conditions and interventions

Interventions

  • ZYN002 - transdermal gel Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
3 Years to 29 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 12, 2021
Primary completion
Aug 28, 2025
Completion
Aug 28, 2025
Last update posted
Dec 16, 2025

2021 – 2025

United States locations

U.S. sites
18
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85016
Science 37 Culver City California 90230
Amnova Clinical Research, LLC Irvine California 92604
Thompson Autism Center CHOC Orange California 92868
UC Davis Health System, MIND Institute Sacramento California 95817
Children's National Medical center Washington D.C. District of Columbia 20010
University of Miami Miami Florida 33136
Rare Disease Research Atlanta Georgia 30318
Rush University Medical Center Chicago Illinois 60612
Kennedy Krieger Institute Baltimore Maryland 21205
Boston Children's Hospital Boston Massachusetts 02115
University of Minnesota Fragile X Clinic (Voyager Clinic) Minneapolis Minnesota 55454
University of Mississippi Jackson Mississippi 39216
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics New York New York 10029
Central States Research Tulsa Oklahoma 74136
Penn State Hershey Medical Center Hershey Pennsylvania 17033
Greenwood Genetic Center Greenville South Carolina 29605
Primary Children's Hospital Salt Lake City Utah 84113

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04977986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04977986 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →